Basic Information
TRIMEZEN MODIFIED-RELEASE TABLETS 35MG
TABLET, FILM COATED, EXTENDED RELEASE
Regulatory Information
SIN16614P
September 28, 2022
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XC01EB15
Company Information
Active Ingredients
Strength: 35mg
Detailed Information
Contraindications
**Contraindications:** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders. Severe renal impairment (creatinine clearance < 30 ml/min).
Indication Information
**Therapeutic indications:** Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to firstline antianginal therapies.